Abstract 391P
Background
Lip cancer represents 1-2% of malgnancies and accounts for 23.6-30% of all oral cancers. It is more common in the lower lip, However, it may appear in the upper lip also. Squamous cell carcinoma is the most common subtype. There is limited data to evaluate racial disparites into different age groups. So this study aims to evaluate the long-term survival outcome for lip cancer in the young and adults compared to the elderly and consider racial disparities.
Methods
Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) Program. We obtained data of patients diagnosed with lip cancer from 2000-2020. The age groups have been classified into two groups according to the National Institute of Age and divided into young and adults if less than 65 years while the old age starting from 65 years.
Results
The majority were Caucasians (99279 patients) and 114 only were African Americans. The 5-year relative survival for lip cancer in the young and adults age group was 92.6%, while in the old age group was 88.9%; P>0.0001. The 5-year relative survival of African Americans in the young and adult age was 85.9% while for Caucasiasns it was 92.5%, and in African Americans elderly the 5-year relative survival was 60.4% while in Caucasian was 88.9%; P >0.0001. The 5-year relative survival for lip cancer in localized SEER stage at the young and adults age group was 95.4%, while in the old age group 92.4% And the 5-year relative survival for lip cancer in distant stage of the disease at young and adults age group was 52.1%, while in the old age group it was 27.7%. Patients treated with combined chemoradiotherapy had a 5-year relative survival of 52.3%, while those who had no systemic therapy had a 5-year relative survival of 93.2%.
Conclusions
In this study, the results highlight significant differences in the long-term survival outcomes; Caucasians are more susceptible to devolop lip cancer than African Americans. However, African Americans have lower survival rates than Caucasians. Due to the early discovery of lip cancer, the standard treatment modality is surgical resection, which explains the significantly decreased survival related to adjuvant chemo(radio)therapy. So we recommend to avoid the systemic therapy for less unfavrouble side effect.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract